Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIREL2: Azacitidine Plus Lenalidomide in Elderly AML and High-Risk MDS
NCT01442714Phase 2Terminated
- Sponsor
- Stanford University
- Start
- Aug 2011
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine, lenalidomide in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Stanford University. Started Aug 2011; status: terminated.
02
Drugs
azacitidinelenalidomide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01442714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01442714.